PTC Therapeutics, Inc.
    SEC Filings

    |
    |

    All SEC filings by PTC Therapeutics, Inc. (PTCT) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.

    Financials

    10-QQuarterly reportView DiffJul 30, 2026
    10-QQuarterly reportView DiffMay 7, 2026
    ARSAnnual report to shareholdersApr 20, 2026
    10-KAnnual reportView DiffFeb 19, 2026
    10-QQuarterly reportView DiffNov 4, 2025
    10-QQuarterly reportView DiffAug 7, 2025
    10-QQuarterly reportView DiffMay 6, 2025
    ARSAnnual report to shareholdersApr 30, 2025
    10-KAnnual reportView DiffFeb 27, 2025
    10-QQuarterly reportView DiffNov 7, 2024

    Events

    8-KCurrent reportAug 28, 2026
    8-KPtc to Expand Rare Disease Portfolio with Acquisition of Bla-Stage St-920 Fabry Disease ProgramAug 13, 2026
    8-KPtc Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial ResultsJul 30, 2026
    8-KCurrent reportJun 18, 2026
    8-KCurrent reportJun 16, 2026
    8-KCurrent reportJun 9, 2026
    8-KCurrent reportJun 5, 2026
    8-KResults of Operations and Financial ConditionMay 7, 2026
    8-KPtc Therapeutics Reports Positive Topline Results From Month 24 Interim Analysis of Pivot-Hd Extension Study of VotoplamApr 28, 2026
    8-KPtc Therapeutics Appoints Biotech Banking PioneerMar 25, 2026

    Registrations and Prospectuses

    POSASRAutomatic shelf registration (post-effective amendment)Nov 7, 2023
    D$35.90 Mm in Equity / Common Stock, Sold $35.90 Mm, 40 InvestorsMay 8, 2023
    S-3ASRAutomatic shelf registrationMay 5, 2023
    POSASRAutomatic shelf registration (post-effective amendment)Apr 28, 2023
    S-8Registration of securities for employeesDec 16, 2022
    S-3ASRAutomatic shelf registrationDec 16, 2022
    S-8Registration of securities for employeesJun 23, 2022
    S-8 POSRegistration of securities for employees (post-effective amendment)Apr 13, 2022
    S-8Registration of securities for employeesJan 5, 2022
    POSASRAutomatic shelf registration (post-effective amendment)Jan 7, 2021

    Proxies

    DEFA14AAdditional proxy soliciting materialsApr 20, 2026
    DEF 14ADefinitive proxyView DiffApr 20, 2026
    DEFA14AAdditional proxy soliciting materialsApr 30, 2025
    DEF 14ADefinitive proxyView DiffApr 30, 2025
    DEFA14AAdditional proxy soliciting materialsApr 26, 2024
    DEF 14ADefinitive proxyView DiffApr 26, 2024
    DEFA14AAdditional proxy soliciting materialsApr 26, 2023
    DEF 14ADefinitive proxyView DiffApr 26, 2023
    DEFA14AAdditional proxy soliciting materialsApr 28, 2022
    DEF 14ADefinitive proxyView DiffApr 28, 2022

    Other

    UPLOADLetter from SECOct 27, 2021
    CT ORDERConfidential treatment orderOct 19, 2021
    CORRESPCorrespondence with SECOct 19, 2021
    UPLOADLetter from SECOct 6, 2021
    CORRESPCorrespondence with SECSep 23, 2021
    UPLOADLetter from SECAug 26, 2021
    CT ORDERConfidential treatment orderSep 17, 2020
    CT ORDERConfidential treatment orderJul 15, 2020
    SEC STAFFSEC staff action: OrderFeb 18, 2020
    SEC STAFFSEC staff action: OrderFeb 7, 2020

    Ownership

    4Schmertzler MichaelAug 28, 2026
    144/ANotice of proposed sale of securitiesAug 25, 2026
    4Schmertzler MichaelAug 21, 2026
    4Boulding Mark ElliottAug 19, 2026
    144Notice of proposed sale of securitiesAug 19, 2026
    144Notice of proposed sale of securitiesAug 17, 2026
    4Klein Matthew B.Aug 6, 2026
    144Notice of proposed sale of securitiesAug 4, 2026
    4Sollie-Zetlmayer Hege ElisabethJul 30, 2026
    3Sollie-Zetlmayer Hege ElisabethJul 30, 2026